AEOL-10150 (Aeolus).

  title={AEOL-10150 (Aeolus).},
  author={Richard W. Orrell},
  journal={Current opinion in investigational drugs},
  volume={7 1},
AEOL-10150, a small-molecule antioxidant analogous to the catalytic site of superoxide dismutase, is under development by Aeolus (formerly Incara) as a potential subcutaneous treatment for amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, lung inflammation and mucositis. The compound is currently undergoing a phase I clinical trial for ALS. In October 2005, the company had applied for Fast Track status, and planned to submit a special protocol assessment for a pivotal phase II… CONTINUE READING